IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow IDXX
Alert me
IDEXX Laboratories, Inc. (IDXX) P/B ratio
As of 5 November 2026, IDEXX Laboratories, Inc. (IDXX) trades at a P/B ratio of 28.2×. Over the past ten years it has ranged from 0.0× (March 2019) to 859× (August 2015); the current reading is higher than 41% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 33.9× | 58.59% |
| FY2024 | 21.4× | (30.26%) |
| FY2023 | 30.6× | (45.05%) |
| FY2022 | 55.8× | (31.40%) |
| FY2021 | 81.3× | 20.61% |
| FY2020 | 67.4× | (46.69%) |
| FY2019 | 126× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 22.0× | (14.56%) |
| Jun 2026 | 25.8× | (10.38%) |
| Mar 2026 | 28.8× | (15.15%) |
| Dec 2025 | 33.9× | 3.40% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| WAT Waters Corporation compare | 2.9× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| IQV IQVIA Holdings Inc. compare | 6.4× |
| A Agilent Technologies, Inc. compare | 6.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| NTRA Natera, Inc. compare | 28.2× |
| IDXX IDEXX Laboratories, Inc. | 28.2× |
| MTD Mettler-Toledo International, Inc. compare | 2,631× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on IDXX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement